Press Release

5001 Spring Valley Road
Suite 500W
Dallas, TX 75244
+1 855.696.6100

Vivione Biosciences Inc. Announces 30 Day Warrant Reduction

DALLAS, TX--(Marketwired - May 04, 2015) - Vivione Biosciences Inc. ("Vivione" or the "Company") (TSX VENTURE: VBI) Further to the Company's press release dated April 22, 2015, the Company has received TSX Venture Exchange approval for the 30 day price amendment to the exercise price of the 12,000,000 common share purchase warrants (the "Warrants") issued to subscribers as part of the Company's prospectus financing which closed on April 19, 2013. The exercise price of the Warrants will be reduced from CDN$0.35 to CDN$0.155 for a 30 day period (the "Price Amendment"). All other terms of the Warrants will remain the same. The Price Amendment will be effective between May 5 and June 4, 2015 (the "Price Reduction Period") and will begin on the date of the Notice (as described below). The Company will deliver a Notice reflecting the amended exercise price, the exact details of the Price Reduction Period and instructions regarding the exercise of the Warrants to the registered holders of the Warrants.

About Vivione
Formed in 2006 in collaboration with the FDA, Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system; an integrated system of hardware, software and chemical reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in food safety, bio-therapeutics, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBIILTY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact Information

Contact:
Mika Bradford
(817) 705-7221
mbradford@vivionebiosciences.com

Disclosure

Please read the terms and conditions section of this website carefully before using the Vivione Biosciences Inc. (the “Company”) web site. By accessing or using this site, you agree to the terms and conditions as set out in the terms and conditions section of this web site. You should review the terms and conditions section regularly as it may change at any time at our sole discretion. If you do not agree to any term or condition, you should not access or otherwise use this site.

General information regarding the Company set forth on the following pages of this website, including management's assessment of the Company's future plans and operations contains forward looking statements that involve substantial known and unknown risks and uncertainties. Wherever possible, words such as "may", ''would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "aim", "endeavour" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs based on its experience and expertise with respect to future events and are based on information currently available to management. Management uses forward-looking statements because it believes they provide useful information with respect to the Company, and cautions readers that the information may not be appropriate for other purposes and should not be read as guarantees of future performance or results.

Forward looking statements are subject to numerous risks and uncertainties, some of which are beyond the management and the Company’s control, including but not limited to, the impact of general economic conditions, industry conditions, fluctuation of foreign exchange rates, imperfection of estimates, industry competition, availability of qualified personnel and management, stock market volatility, timely and cost effective access to sufficient capital from internal and external sources, ability to integrate and realize anticipated benefits from acquisitions, ability to resell third party network communications at favorable rates, and to effectively manage growth. The Company's actual results, performance or achievement could differ materially from those expressed in or implied by, these forward looking statements and accordingly, no assurance can be given that any of the events anticipated to occur or transpire from the forward looking statements will provide any benefits to the Company. All data presented herein should be read in conjunction with the Company's regulatory filings with the appropriate securities regulatory authorities and the System for Electronic Document Analysis and Retrieval (“SEDAR”). Copies of these filings are available for review under the Company's SEDAR profile at www.sedar.com.